Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits

Open access
Denise, Corti, Paoli, Paolo, Calvani, Maura, Taddei, Maria Letizia, Giannoni, Elisa, Kopetz, Scott, Kazmi, Syed Mohammad Ali, Pia, Morelli Maria, Pettazzoni, Piergiorgio, Sacco, Elena, Caselli, Anna, Vanoni, Marco, Landriscina, Matteo, Cirri, Paolo, Chiarugi, Paola · 2015 · Oncotarget

Abstract

// Corti Denise 1, 2, * , Paolo Paoli 1, * , Maura Calvani 1 , Maria Letizia Taddei 1 , Elisa Giannoni 1 , Scott Kopetz 2 , Syed Mohammad Ali Kazmi 2 , Morelli Maria Pia 2 , Piergiorgio Pettazzoni 2 , Elena Sacco 3 , Anna Caselli 1 , Marco Vanoni 3 , Matteo Landriscina 4 , Paolo Cirri 1 , Paola Chiarugi 1 1 Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy 2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 SYSBIO Centre for Systems Biology, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milano, Italy 4 Medical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy * These authors have contributed equally to this work Correspondence to: Paola Chiarugi, e-mail: paola.chiarugi@unifi.it Keywords: cancer metabolism, OXPHOS, chemoresistance, metformin, cancer stem cells Received: July 15, 2015 Accepted: October 09, 2015 Published: October 21, 2015 ABSTRACT Despite marked tumor shrinkage after 5-FU treatment, the frequency of colon cancer relapse indicates that a fraction of tumor cells survives treatment causing tumor recurrence. The majority of cancer cells divert metabolites into anabolic pathways through Warburg behavior giving an advantage in terms of tumor growth. Here, we report that treatment of colon cancer cell with 5-FU selects for cells with mesenchymal stem-like properties that undergo a metabolic reprogramming resulting in addiction to OXPHOS to meet energy demands. 5-FU treatment-resistant cells show a de novo expression of pyruvate kinase M1 (PKM1) and repression of PKM2, correlating with repression of the pentose phosphate pathway, decrease in NADPH level and in antioxidant defenses, promoting PKM2 oxidation and acquisition of stem-like phenotype. Response to 5-FU in a xenotransplantation model of human colon cancer confirms activation of mitochondrial function. Combined treatment with 5-FU and a pharmacological inhibitor of OXPHOS abolished the spherogenic potential of colon cancer cells and diminished the expression of stem-like markers. These findings suggest that inhibition of OXPHOS in combination with 5-FU is a rational combination strategy to achieve durable treatment response in colon cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5991

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 164

Metadata

Authors
Denise, C., Paoli, P., Calvani, M., Taddei, M. L., Giannoni, E., Kopetz, S., Kazmi, S. M. A., Pia, M. M., Pettazzoni, P., Sacco, E., Caselli, A., Vanoni, M., Landriscina, M., Cirri, P., & Chiarugi, P.
Venue
Oncotarget
Published
2015-10-21
Volume
6
Issue
39
Pages
41706-41721
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2173531900
Cited by
164
References
5
FWCI
3.04
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. https://app.cochat.ai/papers/10.18632/oncotarget.5991
The paper
Denise, C., Paoli, P., Calvani, M., Taddei, M. L., Giannoni, E., Kopetz, S., Kazmi, S. M. A., Pia, M. M., Pettazzoni, P., Sacco, E., Caselli, A., Vanoni, M., Landriscina, M., Cirri, P., & Chiarugi, P. (2015). 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. https://doi.org/10.18632/oncotarget.5991

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.